Economic burden of complications and readmission following oesophageal cancer surgery
- PMID: 36129457
- DOI: 10.1111/ans.18062
Economic burden of complications and readmission following oesophageal cancer surgery
Abstract
Background: Oesophageal cancer is the seventh most prevalent malignancy globally, and the sixth most common cause of cancer-related death. Oesophageal cancer is also one of the most costly cancers to treat. The aim of this study was to assess the financial impact of post-operative morbidity and hospital readmissions following oesophagectomy for oesophageal cancer.
Methods: A retrospective analysis was performed on a prospectively maintained database of patients with oesophageal cancer who underwent an oesophagectomy at a single centre between July 2014 and June 2019 (N = 56). Readmission costs were also assessed in this cohort for 12 months post-operatively.
Results: The total median cost for oesophagectomy in this cohort was AU$57 250. Major complications occurred in 40% of patients, with a median total admission cost of AU$74 606, significantly higher than patients with either minor or no complications (median admission cost of AU$52 713, P < 0.001). Patients whose operation was complicated by an anastomotic leak had a higher median admission cost than those without a leak (AU$104 328 and AU$54 972 respectively, P < 0.001). Cost centres representing the greatest proportion of costs were theatre resources and surgical ward care (medical and nursing). A total of 110 readmissions in 25 patients were recorded in the 12 months post-operatively, the majority for gastroscopy and dilatation of anastomotic stricture.
Conclusion: Post-oesophagectomy morbidity greatly increases cost of care. In addition to the clinical benefits, interventions to minimize post-operative complications are likely to result in substantial cost savings.
Keywords: cost savings; esophagectomy; hospital costs; oesophageal neoplasms; patient readmission.
© 2022 Royal Australasian College of Surgeons.
Comment in
-
Real cost of surgery: what are we missing?ANZ J Surg. 2022 Dec;92(12):3126-3127. doi: 10.1111/ans.18160. ANZ J Surg. 2022. PMID: 36527692 No abstract available.
References
-
- Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71: 209-49.
-
- Watanabe M, Otake R, Kozuki R et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg. Today 2020; 50: 12-20.
-
- de Oliveira C, Pataky R, Bremner KE et al. Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer 2016; 16: 809.
-
- Thein HH, Jembere N, Thavorn K et al. Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study. BMC Cancer 2018; 18: 694.
-
- Tramontano AC, Chen Y, Watson TR, Eckel A, Hur C, Kong CY. Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013. Cancer Med. 2019; 8: 5158-72.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical